User menu

The Human Vaccines Project: A roadmap for cancer vaccine development

Bibliographic reference Romero, P. ; Banchereau, J. ; Bhardwaj, N. ; Cockett, M. ; Disis, M. L. ; et. al. The Human Vaccines Project: A roadmap for cancer vaccine development. In: Science Translational Medicine, Vol. 8, no.334, p. 334ps9-334ps9 (2016)
Permanent URL
  1. Rosenberg Steven A, Yang James C, Restifo Nicholas P, Cancer immunotherapy: moving beyond current vaccines, 10.1038/nm1100
  2. Melero Ignacio, Gaudernack Gustav, Gerritsen Winald, Huber Christoph, Parmiani Giorgio, Scholl Suzy, Thatcher Nicholas, Wagstaff John, Zielinski Christoph, Faulkner Ian, Mellstedt Håkan, Therapeutic vaccines for cancer: an overview of clinical trials, 10.1038/nrclinonc.2014.111
  3. Obeid Joseph, Hu Yinin, Slingluff Craig L., Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges, 10.1053/j.seminoncol.2015.05.006
  4. Pol Jonathan, Bloy Norma, Buqué Aitziber, Eggermont Alexander, Cremer Isabelle, Sautès-Fridman Catherine, Galon Jérôme, Tartour Eric, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo, Trial Watch: Peptide-based anticancer vaccines, 10.4161/2162402x.2014.974411
  5. Speiser Daniel E., Romero Pedro, Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity, 10.1016/j.smim.2010.03.004
  6. Thomas A., Giaccone G., Why has active immunotherapy not worked in lung cancer?, 10.1093/annonc/mdv323
  7. Melief Cornelis J.M., van Hall Thorbald, Arens Ramon, Ossendorp Ferry, van der Burg Sjoerd H., Therapeutic cancer vaccines, 10.1172/jci80009
  8. Topalian Suzanne L., Drake Charles G., Pardoll Drew M., Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, 10.1016/j.ccell.2015.03.001
  9. Gubin Matthew M., Zhang Xiuli, Schuster Heiko, Caron Etienne, Ward Jeffrey P., Noguchi Takuro, Ivanova Yulia, Hundal Jasreet, Arthur Cora D., Krebber Willem-Jan, Mulder Gwenn E., Toebes Mireille, Vesely Matthew D., Lam Samuel S. K., Korman Alan J., Allison James P., Freeman Gordon J., Sharpe Arlene H., Pearce Erika L., Schumacher Ton N., Aebersold Ruedi, Rammensee Hans-Georg, Melief Cornelis J. M., Mardis Elaine R., Gillanders William E., Artyomov Maxim N., Schreiber Robert D., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, 10.1038/nature13988
  10. Yadav Mahesh, Jhunjhunwala Suchit, Phung Qui T., Lupardus Patrick, Tanguay Joshua, Bumbaca Stephanie, Franci Christian, Cheung Tommy K., Fritsche Jens, Weinschenk Toni, Modrusan Zora, Mellman Ira, Lill Jennie R., Delamarre Lélia, Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing, 10.1038/nature14001
  11. Gajewski Thomas F., The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment, 10.1053/j.seminoncol.2015.05.011
  12. Motz Gregory T, Santoro Stephen P, Wang Li-Ping, Garrabrant Tom, Lastra Ricardo R, Hagemann Ian S, Lal Priti, Feldman Michael D, Benencia Fabian, Coukos George, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors, 10.1038/nm.3541
  13. Schumacher T. N., Schreiber R. D., Neoantigens in cancer immunotherapy, 10.1126/science.aaa4971
  14. Pulendran B., Systems vaccinology: Probing humanity's diverse immune systems with vaccines, 10.1073/pnas.1400476111
  15. Koff W. C., Burton D. R., Johnson P. R., Walker B. D., King C. R., Nabel G. J., Ahmed R., Bhan M. K., Plotkin S. A., Accelerating Next-Generation Vaccine Development for Global Disease Prevention, 10.1126/science.1232910
  16. Koff Wayne C, Gust Ian D, Plotkin Stanley A, Toward a Human Vaccines Project, 10.1038/ni.2871
  17. Schenkelberg Theodore, Kieny Marie-Paule, Bianco AE, Koff Wayne C, Building the Human Vaccines Project: strategic management recommendations and summary report of the 15–16 July 2014 business workshop, 10.1586/14760584.2015.1013466
  18. Neller Michelle A., López J. Alejandro, Schmidt Christopher W., Antigens for cancer immunotherapy, 10.1016/j.smim.2008.09.006
  19. Eggermont Alexander M.M., Therapeutic vaccines in solid tumours: Can they be harmful?, 10.1016/j.ejca.2009.05.004
  20. Journal of Clinical Oncology, 25, 8508 (2007)
  21. Jocham Dieter, Richter Axel, Hoffmann Lothar, Iwig Klaus, Fahlenkamp Dirk, Zakrzewski Günther, Schmitt Eberhard, Dannenberg Thomas, Lehmacher Walter, von Wietersheim Jörn, Doehn Christian, Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial, 10.1016/s0140-6736(04)15590-6
  22. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, 10.1126/science.1840703
  23. Coulie Pierre G., Van den Eynde Benoît J., van der Bruggen Pierre, Boon Thierry, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy, 10.1038/nrc3670
  24. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., Pfreundschuh M., Human neoplasms elicit multiple specific immune responses in the autologous host., 10.1073/pnas.92.25.11810
  25. Rizvi N. A., Hellmann M. D., Snyder A., Kvistborg P., Makarov V., Havel J. J., Lee W., Yuan J., Wong P., Ho T. S., Miller M. L., Rekhtman N., Moreira A. L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E. B., Merghoub T., Wolchok J. D., Schumacher T. N., Chan T. A., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, 10.1126/science.aaa1348
  26. Snyder Alexandra, Makarov Vladimir, Merghoub Taha, Yuan Jianda, Zaretsky Jesse M., Desrichard Alexis, Walsh Logan A., Postow Michael A., Wong Phillip, Ho Teresa S., Hollmann Travis J., Bruggeman Cameron, Kannan Kasthuri, Li Yanyun, Elipenahli Ceyhan, Liu Cailian, Harbison Christopher T., Wang Lisu, Ribas Antoni, Wolchok Jedd D., Chan Timothy A., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, 10.1056/nejmoa1406498
  27. Rooney Michael S., Shukla Sachet A., Wu Catherine J., Getz Gad, Hacohen Nir, Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity, 10.1016/j.cell.2014.12.033
  28. Cheever M. A., Allison J. P., Ferris A. S., Finn O. J., Hastings B. M., Hecht T. T., Mellman I., Prindiville S. A., Viner J. L., Weiner L. M., Matrisian L. M., The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research, 10.1158/1078-0432.ccr-09-0737
  29. Carreno B. M., Magrini V., Becker-Hapak M., Kaabinejadian S., Hundal J., Petti A. A., Ly A., Lie W.-R., Hildebrand W. H., Mardis E. R., Linette G. P., A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, 10.1126/science.aaa3828
  30. Pinto Sheena, Sommermeyer Daniel, Michel Chloé, Wilde Susanne, Schendel Dolores, Uckert Wolfgang, Blankenstein Thomas, Kyewski Bruno, Misinitiation of intrathymicMART-1transcription and biased TCR usage explain the high frequency of MART-1-specific T cells : Clinical immunology, 10.1002/eji.201444499
  31. Romero Pedro, Speiser Daniel E., Rufer Nathalie, Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans, 10.1002/eji.201445004
  32. Derbinski J., Pinto S., Rosch S., Hexel K., Kyewski B., Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism, 10.1073/pnas.0707486105
  33. Palucka Karolina, Banchereau Jacques, Cancer immunotherapy via dendritic cells, 10.1038/nrc3258
  34. Kantoff Philip W., Schuetz Thomas J., Blumenstein Brent A., Glode L. Michael, Bilhartz David L., Wyand Michael, Manson Kelledy, Panicali Dennis L., Laus Reiner, Schlom Jeffrey, Dahut William L., Arlen Philip M., Gulley James L., Godfrey Wayne R., Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer, 10.1200/jco.2009.25.0597
  35. Rothman John, Paterson Yvonne, Live-attenuatedListeria-based immunotherapy, 10.1586/erv.13.34
  36. Kaufman Howard L, Ruby Carl E, Hughes Tasha, Slingluff Craig L, Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma, 10.1186/2051-1426-2-11
  37. Brudno Yevgeny, Mooney David J., On-demand drug delivery from local depots, 10.1016/j.jconrel.2015.09.011
  38. Schiller John T., Lowy Douglas R., Understanding and learning from the success of prophylactic human papillomavirus vaccines, 10.1038/nrmicro2872
  39. Carter R. W., Thompson C., Reid D. M., Wong S. Y. C., Tough D. F., Preferential Induction of CD4+ T Cell Responses through In Vivo Targeting of Antigen to Dendritic Cell-Associated C-Type Lectin-1, 10.4049/jimmunol.177.4.2276
  40. Idoyaga J., Lubkin A., Fiorese C., Lahoud M. H., Caminschi I., Huang Y., Rodriguez A., Clausen B. E., Park C. G., Trumpfheller C., Steinman R. M., Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A, 10.1073/pnas.1019547108
  41. Klechevsky E., Flamar A.-L., Cao Y., Blanck J.-P., Liu M., O'Bar A., Agouna-Deciat O., Klucar P., Thompson-Snipes L., Zurawski S., Reiter Y., Palucka A. K., Zurawski G., Banchereau J., Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR, 10.1182/blood-2010-01-264960
  42. Speiser Daniel E., Liénard Danielle, Rufer Nathalie, Rubio-Godoy Verena, Rimoldi Donata, Lejeune Ferdy, Krieg Arthur M., Cerottini Jean-Charles, Romero Pedro, Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909, 10.1172/jci200523373
  43. Perret R., Sierro S. R., Botelho N. K., Corgnac S., Donda A., Romero P., Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity, 10.1158/0008-5472.can-13-0875
  44. Apostolou Irina, von Boehmer Harald, In Vivo Instruction of Suppressor Commitment in Naive T Cells, 10.1084/jem.20040249
  45. Rosalia Rodney A., Quakkelaar Esther D., Redeker Anke, Khan Selina, Camps Marcel, Drijfhout Jan W., Silva Ana Luisa, Jiskoot Wim, van Hall Thorbald, van Veelen Peter A., Janssen George, Franken Kees, Cruz Luis J., Tromp Angelino, Oostendorp Jaap, van der Burg Sjoerd H., Ossendorp Ferry, Melief Cornelis J. M., Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation : Antigen processing, 10.1002/eji.201343324
  46. Carbone David P., Ciernik I. Frank, Kelley Michael J., Smith M. Charles, Nadaf Sorena, Kavanaugh Denise, Maher V. Ellen, Stipanov Michael, Contois David, Johnson Bruce E., Pendleton C. David, Seifert Burkhardt, Carter Charley, Read Elizabeth J., Greenblatt Jay, Top Lois E., Kelsey Morris I., Minna John D., Berzofsky Jay A., Immunization With Mutantp53- andK-ras–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome, 10.1200/jco.2005.03.158
  47. Kenter Gemma G., Welters Marij J.P., Valentijn A. Rob P.M., Lowik Margriet J.G., Berends-van der Meer Dorien M.A., Vloon Annelies P.G., Essahsah Farah, Fathers Lorraine M., Offringa Rienk, Drijfhout Jan Wouter, Wafelman Amon R., Oostendorp Jaap, Fleuren Gert Jan, van der Burg Sjoerd H., Melief Cornelis J.M., Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia, 10.1056/nejmoa0810097
  48. Yewdell Jonathan W, Designing CD8+ T cell vaccines: it's not rocket science (yet), 10.1016/j.coi.2010.04.002
  49. Stevenson Freda K., Mander Ann, Chudley Lindsey, Ottensmeier Christian H., DNA fusion vaccines enter the clinic, 10.1007/s00262-011-1042-2
  50. Williams James, Improving DNA Vaccine Performance Through Vector Design, 10.2174/156652321403140819122538
  51. Trimble Cornelia L, Morrow Matthew P, Kraynyak Kimberly A, Shen Xuefei, Dallas Michael, Yan Jian, Edwards Lance, Parker R Lamar, Denny Lynette, Giffear Mary, Brown Ami Shah, Marcozzi-Pierce Kathleen, Shah Divya, Slager Anna M, Sylvester Albert J, Khan Amir, Broderick Kate E, Juba Robert J, Herring Timothy A, Boyer Jean, Lee Jessica, Sardesai Niranjan Y, Weiner David B, Bagarazzi Mark L, Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial, 10.1016/s0140-6736(15)00239-1
  52. Sahin Ugur, Karikó Katalin, Türeci Özlem, mRNA-based therapeutics — developing a new class of drugs, 10.1038/nrd4278
  53. Kübler Hubert, Scheel Birgit, Gnad-Vogt Ulrike, Miller Kurt, Schultze-Seemann Wolfgang, vom Dorp Frank, Parmiani Giorgio, Hampel Christian, Wedel Steffen, Trojan Lutz, Jocham Dieter, Maurer Tobias, Rippin Gerd, Fotin-Mleczek Mariola, von der Mülbe Florian, Probst Jochen, Hoerr Ingmar, Kallen Karl-Josef, Lander Thomas, Stenzl Arnulf, Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study, 10.1186/s40425-015-0068-y
  54. Kaech Susan M., Cui Weiguo, Transcriptional control of effector and memory CD8+ T cell differentiation, 10.1038/nri3307
  55. Rao Rajesh R., Li Qingsheng, Bupp Melanie R. Gubbels, Shrikant Protul A., Transcription Factor Foxo1 Represses T-bet-Mediated Effector Functions and Promotes Memory CD8+ T Cell Differentiation, 10.1016/j.immuni.2012.01.015
  56. Böttcher Jan, Knolle Percy A., Global transcriptional characterization of CD8+ T cell memory, 10.1016/j.smim.2015.03.001
  57. Araki Koichi, Turner Alexandra P., Shaffer Virginia Oliva, Gangappa Shivaprakash, Keller Susanne A., Bachmann Martin F., Larsen Christian P., Ahmed Rafi, mTOR regulates memory CD8 T-cell differentiation, 10.1038/nature08155
  58. Pearce Erika L., Walsh Matthew C., Cejas Pedro J., Harms Gretchen M., Shen Hao, Wang Li-San, Jones Russell G., Choi Yongwon, Enhancing CD8 T-cell memory by modulating fatty acid metabolism, 10.1038/nature08097
  59. Berezhnoy Alexey, Castro Iris, Levay Agata, Malek Thomas R., Gilboa Eli, Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity, 10.1172/jci69856
  60. Utzschneider Daniel T, Legat Amandine, Fuertes Marraco Silvia A, Carrié Lucie, Luescher Immanuel, Speiser Daniel E, Zehn Dietmar, T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion, 10.1038/ni.2606
  61. Speiser Daniel E., Utzschneider Daniel T., Oberle Susanne G., Münz Christian, Romero Pedro, Zehn Dietmar, T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?, 10.1038/nri3740
  62. Brodin Petter, Jojic Vladimir, Gao Tianxiang, Bhattacharya Sanchita, Angel Cesar J. Lopez, Furman David, Shen-Orr Shai, Dekker Cornelia L., Swan Gary E., Butte Atul J., Maecker Holden T., Davis Mark M., Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences, 10.1016/j.cell.2014.12.020
  63. 40, 436 (2014)
  64. 39, 61 (2013)
  65. Solito Samantha, Marigo Ilaria, Pinton Laura, Damuzzo Vera, Mandruzzato Susanna, Bronte Vincenzo, Myeloid-derived suppressor cell heterogeneity in human cancers : Myeloid-derived suppressor cell heterogeneity, 10.1111/nyas.12469
  66. Garon Edward B., Rizvi Naiyer A., Hui Rina, Leighl Natasha, Balmanoukian Ani S., Eder Joseph Paul, Patnaik Amita, Aggarwal Charu, Gubens Matthew, Horn Leora, Carcereny Enric, Ahn Myung-Ju, Felip Enriqueta, Lee Jong-Seok, Hellmann Matthew D., Hamid Omid, Goldman Jonathan W., Soria Jean-Charles, Dolled-Filhart Marisa, Rutledge Ruth Z., Zhang Jin, Lunceford Jared K., Rangwala Reshma, Lubiniecki Gregory M., Roach Charlotte, Emancipator Kenneth, Gandhi Leena, Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer, 10.1056/nejmoa1501824
  67. Le D. T., Jaffee E. M., Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective, 10.1158/0008-5472.can-11-3912
  68. van der Sluis T. C., van Duikeren S., Huppelschoten S., Jordanova E. S., Beyranvand Nejad E., Sloots A., Boon L., Smit V. T. H. B. M., Welters M. J. P., Ossendorp F., van de Water B., Arens R., van der Burg S. H., Melief C. J. M., Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death, 10.1158/1078-0432.ccr-14-2142